Residual risk in patients with atherosclerotic cardiovascular disease
Open Access
- 6 January 2023
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (1) , 3382
Abstract
The residual risk in patients with atherosclerosis, despite the its controversial aspects, remains an urgent problem of modern cardiology. The article presents a review of publications on the prevalence and significance for determining the prognosis of residual risk, which is currently interpreted as the risk of macroand microvascular complications in patients with atherosclerotic cardiovascular disease (ACVD) taking standard therapy, with the achievement of optimal levels of low-density lipoprotein cholesterol, blood pressure and glucose. Based on available publications, we highlighted current views on the factors associated with residual inflammatory and lipid risks in ACVD patients, including those associated with heart failure and diabetes, and the prognostic significance of residual risk in such patients. An attempt was made to rationale the significance of determining the residual risk for secondary prevention of cardiovascular events.Keywords
This publication has 36 references indexed in Scilit:
- Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosisRational Pharmacotherapy in Cardiology, 2015
- Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular EventsJACC, 2014
- Residual macrovascular risk in 2013: what have we learned?Cardiovascular Diabetology, 2014
- Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsJAMA, 2012
- A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular RiskCirculation: Cardiovascular Quality and Outcomes, 2011
- The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitusClinical Lipidology, 2011
- Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trialThe Lancet, 2009
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008
- Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and PreventionCirculation, 2003
- Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival studyBMJ, 1998